Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

March 26, 2021

Study Completion Date

June 25, 2021

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

SOF/VEL

Tablets administered orally once daily

Trial Locations (22)

2701694

Nippon Medical School Hospital, Inzai-shi

7908524

Matsuyama Red Cross Hospital, Matsuyama

260-8677

Chiba University Hospital, Chiba

918-8503

Fukui-ken Saiseikai Hospital, Fukui

815-8555

Japanese Red Cross Fukuoka Hospital, Fukuoka

734-8551

Hiroshima University Hospital Institution Review Board, Hiroshima

820-8505

Iizuka Hospital, Iizuka

350-0495

Saitama Medical University Hospital, Iruma

410-2295

Juntendo University Shizuoka Hospital, Izunokuni

634-8522

Nara Medical University Hospital, Kashihara-shi

213-8587

Toranomon Hospital Kajigaya, Kawasaki-shi

862-8655

Kumamoto Shinto General Hospital, Kumamoto

830-0011

Kurme University Hospital, Kurume-shi

180-8610

Japanese Red Cross Musashino Hospital, Musashino

663-8501

Hyogo College of Medicine Hospital Institutional Review Board, Nishinomiya

856-8562

National Hospital Organization Nagasaki Medical Center, Omura-shi

543-8555

Osaka Red Cross Hospital, Osaka

545-8586

Osaka City University Hospital, Osaka

060-0033

Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital, Sapporo

565-0871

Osaka University Hospital, Suita-shi

760-8557

Kagawa Prefectural Central Hospital, Takamatsu

105-8470

Toranomon Hospital, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY